Nationwide Fund Advisors’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-452,798
Closed -$84.4M 103
2017
Q3
$84.4M Sell
452,798
-35,927
-7% -$6.37M 0.33% 35
2017
Q2
$84.2M Sell
488,725
-68,872
-12% -$11.2M 0.34% 32
2017
Q1
$91.5M Sell
557,597
-32,662
-6% -$5.43M 0.37% 30
2016
Q4
$86.3M Sell
590,259
-92,610
-14% -$13.9M 0.36% 31
2016
Q3
$114M Buy
682,869
+51,030
+8% +$8.63M 0.48% 24
2016
Q2
$96.1M Buy
631,839
+22,751
+4% +$3.54M 0.42% 27
2016
Q1
$91.3M Buy
609,088
+19,914
+3% +$2.96M 0.4% 28
2015
Q4
$95.6M Buy
589,174
+262,126
+80% +$41.2M 0.41% 33
2015
Q3
$45.2M Sell
327,048
-2,898
-0.9% -$457K 0.2% 87
2015
Q2
$50.7M Sell
329,946
-68,098
-17% -$10.9M 0.21% 79
2015
Q1
$63.6M Sell
398,044
-23,970
-6% -$3.78M 0.26% 59
2014
Q4
$67.2M Sell
422,014
-5,450
-1% -$849K 0.29% 48
2014
Q3
$60M Buy
427,464
+1,418
+0.3% +$185K 0.25% 59
2014
Q2
$50.4M Buy
+426,046
New +$49.3M 0.21% 90
2014
Q1
Sell
-624,014
Closed -$71.2M 3093
2013
Q4
$71.2M Buy
624,014
+11,391
+2% +$1.3M 0.3% 50
2013
Q3
$68.6M Buy
612,623
+57,611
+10% +$6.25M 0.31% 47
2013
Q2
$54.8M Buy
+555,012
New +$57.6M 0.29% 58

Other funds holding AMGN

Nationwide Fund Advisors's AMGN Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Amgen (AMGN) in Q4 2017, closing a stake of 452,798 shares — an estimated $84.4M sold.

Nationwide Fund Advisors first reported a position in AMGN in Q2 2013 and held it in 17 quarters. The position peaked at $114M in Q3 2016. 1,735 funds tracked by Wall St. Rank hold AMGN as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Amgen position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 452,798 Amgen shares in Q4 2017, an estimated $84.4M.
  • Nationwide Fund Advisors first reported a position in Amgen in Q2 2013 and held it in 17 quarters.
  • Nationwide Fund Advisors's Amgen position peaked at $114M in Q3 2016.
  • 1,735 funds tracked by Wall St. Rank held Amgen as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.